Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
2024年5月31日 - 9:00PM
ビジネスワイヤ(英語)
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical
company focused on discovering and developing potential
best-in-class medicines for serious and rare diseases, today
announced that senior management will participate in the following
upcoming investor conferences in June:
- Jefferies Global Healthcare Conference
(New York, NY): Presentation on Wednesday, June 5, 2024, at
5:00 p.m. ET.
- Goldman Sachs 45th Annual Global
Healthcare Conference (Miami, FL): Presentation on Tuesday
June 11, 2024, at 8:40 a.m. ET.
A live webcast of each presentation can be accessed under
“Events and Presentations” on the Investors section of the Viridian
website at viridiantherapeutics.com. A replay of the webcasts will
be available following the completion of the event.
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on engineering
and developing potential best-in-class medicines for patients with
serious and rare diseases. Viridian’s expertise in antibody
discovery and protein engineering enables the development of
differentiated therapeutic candidates for previously validated drug
targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the
treatment of patients with thyroid eye disease (TED). The company
is conducting a pivotal program for VRDN-001, including two global
phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate its
efficacy and safety in patients with active and chronic TED.
Viridian’s goal is to advance VRDN-001 as a potential best-in-class
intravenous therapy followed by VRDN-003 as a potential
best-in-class subcutaneous therapy for the treatment of TED.
In addition to its TED portfolio, Viridian is advancing a novel
portfolio of neonatal Fc receptor (FcRn) inhibitors, including
VRDN-006 and VRDN-008, which has the potential to be developed in
multiple autoimmune diseases.
Viridian is based in Waltham, Massachusetts. For more
information, please visit www.viridiantherapeutics.com. Follow
Viridian on LinkedIn and X.
Source: Viridian Therapeutics, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240531086999/en/
Louisa Stone, 617-272-4604 Manager, Investor Relations
IR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 5 2024 まで 6 2024
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 6 2023 まで 6 2024